Our fully integrated dermatological service allows front-line healthcare providers to seamlessly consult with dermatologists to offer more effective and efficient patient care..
A patient or healthcare provider identifies a pigmented lesion that should be assessed by a dermatologist.
That’s where we come in.
Our SIAscope is a hand-held Class IIA medical device and the only image-capture technology on the market that provides clinical, dermascopic and spectrophotometric views of moles up to 2 mm below the skin’s surface. Our technology allows healthcare providers, like physicians, pharmacists and healthcare technicians, to capture perfect clinical images with 100% image integrity. Currently approximately 40% of images sent using existing teledermatology platforms cannot be successfully assessed by a dermatologist because of poor image quality. MedX’s advanced imaging technology solves this major issue facing dermatologists wanting to adopt teledermatology in their practice.
SIAscopy on DermSecure™ is our secure, cloud-based telemedicine platform and patient management system — it captures the dermatological images from the SIAscope and forwards them for assessment by a dermatologist. These high-quality images, coupled with a patient management work flow specifically designed for dermatological e-consults, provides a rapid assessment platform for clinicians to ensure patients with suspicious pigmented lesions can be assessed swiftly by a dermatologist and the most urgent cases are given expedited treatment.
A dermatologist assesses the patient’s suspicious mole or lesion within two business days. The quality of the images facilitates an accurate assessment.
Healthcare providers and patients receive secure access to detailed assessment reports and next steps. MedX stores patient’s information for 10 years, which means a patient can retrieve their patient file and take another scan of the same mole or lesion years later and compare it to previous images to see if there has been any change. MedX is the only company in the world that has made this commitment to the patient and their providers.
What you see. The only dermatology device with standardized, fixed-focallength clinical, dermascopic, spectrophotometric views of a suspicious mole or lesion.
It will change how you work. Seamless integration with EMR platforms allows for a more effective, efficient and collaborative workflow, resulting in improved patient outcomes.
The professional choice. We design, develop and test in collaboration with dermatologists and primary healthcare providers. We have regulatory approvals in 35 countries including USA, Canada, Australia, Brazil, and the EU.
Cybersecurity assurance. Our commitment to security and safety is a top priority.